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Abstract
Background: Drug use and in particular injecting drug use has been at the forefront of the
explosive spread of HIV in general populations in many countries in Asia. There is concern that also
in China increased HIV incidence in drug users might spark off a generalized epidemic in the wider
population. Close monitoring of HIV incidence and risk factors in drug users is therefore important
to be able to target interventions effectively. Second generation surveillance was launched to assess
HIV prevalence and risk behaviours jointly with the purpose of describing trends and predicting
future developments. To assess whether these goals were fulfilled among drug users in China we
provide an analysis of risk factors for HIV infection and of regional differences in HIV prevalence.
Methods: We analysed data collected in 2005 in 21 drug user second generation surveillance
sentinel sites from 14 provinces in China. We used random effects logistic regression to test for
risk factors for HIV infection and regional differences.
Results: The overall HIV-1 antibody prevalence was 5.4% (279/5128); 4.9% among injecting drug
users (IDU) not sharing needles and 3.7% among non-injecting drug users. We found substantial
heterogeneity among the surveillance sites with prevalence rates ranging between 0% and 54%. HIV
status was strongly affected by the regional prevalence of HIV. Risk behaviours were highly
prevalent in regions where HIV prevalence is still low. The distribution of duration of drug use in
different sites indicated different stages of the drug use epidemics.
Conclusion: ]Regional differences in HIV prevalence in China reflect different stages of the drug
use and HIV epidemics rather than differences in risk behaviours. Therefore, outbreaks of HIV
among drug users in regions where prevalence is still low can be expected in the future. However,
methodological limitations of surveillance embedded into routine systems limit the usability of
existing data. More standardized approaches to data collection in secondary generation HIV
surveillance are necessary to better understand regional differences in risk behaviour and
prevalence and to design targeted intervention for those regions at risk of experiencing outbreaks.
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The first recognized outbreak of HIV in China occurred in
1989 in Ruili City, Yunnan Province, among injecting
drug users (IDU)[1]. In the years to follow HIV spread
explosively among IDU populations in Yunnan province
and subsequently in neighbouring provinces. In 1995 a
sentinel surveillance system was initiated, the so-called
first generation surveillance. Only in 2001 the Chinese
government acknowledged the existence of a major epi-
demic and changed its course to more openness and
proactive behaviour to control the increasing HIV/AIDS
problem [2]. With international support from the World
Health Organization (WHO) and the Joint United
Nations Programme on HIV/AIDS (UNAIDS), a first pub-
lished estimate of the size of the problem was derived
combining estimates of the sizes of risk populations in the
various provinces with estimates of HIV prevalence per
risk group available from national surveillance sites in
2003. The main risk groups considered in this estimation
were IDU, men who have sex with men (MSM), paid
blood donors infected by unsafe equipment, and com-
mercial sex workers (CSW). It was estimated that there
were between 650,000 and 1.2 million people living with
HIV in China in 2003. Newer estimates tend to be some-
what lower and put the number of people living with HIV
in 2005 between 540,000 and 760,000, the number of
new HIV infections in 2005 at 70,000 to 80,000 and
25,000 AIDS deaths [3]. There is substantial regional het-
erogeneity in HIV prevalence with those provinces border-
ing to the Golden Triangle, where drug trafficking is
common, having the highest HIV prevalences, especially
among IDU. In the prefectures of Yunnan and Xinjiang
prevalences of up to 80% among IDU have been reported
[4,5]. Also in the provinces of Sichuan, Guizhou and
Guangxi prevalences of around 50% among IDU have
been reported [6].
In recent years the Chinese government has intensified its
surveillance programme [7], which consists of: a) case
reporting through an internet based surveillance tool, b)
sentinel sites where mainly prevalence data is collected,
and c) second generation surveillance sites where preva-
lence and behavioural data are collected, d) in depth epi-
demiological investigations [8]. The sentinel surveillance
has been expanded to include 194 sites in 2003, of which
49 are drug-user sites from 21 provinces. Following rec-
ommendations by WHO for implementing second gener-
ation surveillance [9], another set of surveillance sites was
established specifically for collecting behavioural data
aimed at monitoring trends in risk behaviour and the
prevalence of other sexually transmitted infections (STI)
such as syphilis. At present, there are 105 sites for second
generation surveillance. The sites were chosen according
to numbers of case reports in the national surveillance
and other epidemiological considerations. Concerning
drug users, provinces with HIV prevalence above 5% have
to have at least one sentinel surveillance site collecting
behavioural information; in other provinces sites can be
chosen based on factors like local socio-economic level,
local health care facilities, and the size of floating popula-
tions. In 2005, 21 sites in 14 provinces collected behav-
ioural data in drug users.
Persons identified as drug users in China are registered in
a database of the Ministry of Public Security. The numbers
of registered drug users have risen from 70,000 in 1989 to
1,140,000 in 2004 [10]. It was also estimated that the
total population of drug users in 2004 was around 3.5
million and thus about three times as large as the number
of registered drug users [11,12]. It is estimated that among
drug users about 54% are injecting drug users and of those
about 45% have recently shared needles and other inject-
ing equipment [13,14]. Large regional differences exist,
however, with the highest rates of injecting and needle
sharing observed in the southwest provinces and Xinjiang.
Also, it has been shown that a correlation exists between
high risk injecting and high risk sexual behaviour in male
injecting drug users [15].
Although up to now the epidemic in China has remained
concentrated in risk groups, there is increasing concern
that HIV might spread via bridge populations such as
female sex workers [16,17] or surplus men [18] into the
general population. Many female IDU are also CSWs and
commonly engage in unprotected sex [19]. Recently, a
molecular epidemiological study has shown increased cir-
culation of sexually transmitted HIV in Yunnan, the prov-
ince with the first and largest HIV epidemic among IDU
[20].
In view of the imminent threat of large scale spread of HIV
into the general population of China a surveillance system
that allows reliable monitoring of the epidemic and of
possible changes in risk behaviour is important. Second
generation surveillance of drug users was implemented in
1999 and since then scaled up to the present dimension.
Here we analyse data from second generation surveillance
among drug users conducted in 2005 with data collected
in 21 drug user sentinel sites from 14 provinces. While
most studies have focussed on the HIV epidemic in south-
west China [14] we report on data from sites all over the
country. In this analysis we focus on the geographical dif-
ferences of HIV prevalence and drug use. The prevalence
of syphilis and implications for the further sexual spread
of HIV will be analyzed elsewhere. Central aims of second
generation HIV surveillance are focussing surveillance on
subgroups of the population at highest risk of infection
and implementing surveillance that moves with the needs
and state of the epidemic [21]. We present results that
contribute to assessing whether those aims can be reachedPage 2 of 11
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and what the main limitations of the collected data are in
this respect.
Methods
Choice of second generation surveillance sites and study 
population
In 2005, based on the HIV prevalence obtained from the
HIV/AIDS case reporting system in 2004 and other epide-
miological studies, 22 drug user sites from 14 provinces
were initially selected to perform a behavioural survey.
Each site was asked to recruit between 300 and 400 partic-
ipants. This number was considered sufficient for descrip-
tive purposes and to estimate prevalence with 95%
confidence intervals of +/- 5% (for prevalence rates below
30%). Persons to be included were drug users who smoke
or intravenously or intramuscularly use heroin, cocaine,
opium, marijuana, morphine, methamphetamine hydro-
chloride, Pethidine, K powder (Ketamine), or Methylene-
dioxymethamphetamine (MDMA, also known as
Ecstasy). In order to avoid prosecution by law and
increase participation, anonymity and confidentiality
were guaranteed to the drug users when they participated
in the survey. Recruitment followed convenience sam-
pling: some participants were recruited from detoxifica-
tion centres, others in public meeting places where drugs
are consumed, and finally in bars and outreach projects.
In some cases snowball sampling was also used. The pro-
portions recruited from these settings differed between
different sites due to different local circumstances.
The data collection period was from July to September
2005, but could be prolonged in case a site was not able
to recruit the requested number of participants within that
time period. If the required sample size was not reached
by the end of the year, local investigators contacted China
Center for Disease Control and Prevention who then
decided whether or not to end the sampling process. All
participants were asked to complete a questionnaire on
demographic and behavioural issues and to provide a
blood specimen for HIV antibody testing. One site in Kun-
ming, Yunnan province was excluded from our analysis
because information about risk behaviour of drug users
was missing. The protocol "HIV Surveillance Protocol at
National Comprehensive (second generation surveil-
lance) HIV Sentinel Sites", was approved by the national
ethical committee of China [7]. The protocol requires
informed consent from participants in behavioural sur-
veillance.
HIV testing
The blood specimens were collected on-site and tested at
the provincial CDC. Two Enzyme-linked Immunosorbent
Assays (ELISA) were used for testing for HIV antibodies.
For blood specimen with a positive result in the first
ELISA, a second (different) ELISA assay was performed
(first HIV ELISA test: ELISA reagent: (Wantai Biotech, Bei-
jing, China); second HIV ELISA test: ELISA reagent (Viron-
ostika HIV Uniform II Ag/Ab. Akzo Organon Teknika,
Netherlands). Specimens with positive results in both
ELISA assays were considered positive for HIV.
Behavioural survey
Information asked in the questionnaire included recruit-
ment setting, gender, age, marital status, place of resi-
dence, ethnicity, educational background, profession,
monthly income, age at first drug use, injecting drug use
and needle sharing, number of commercial sex partners in
last 12 months, and STI symptoms in last 12 months. In
addition to the behavioural risk factors, knowledge about
transmission routes of HIV (six questions: "can HIV be
recognized from appearance?"; "can HIV be transmitted
by blood products?"; "by needle sharing?"; "from mother
to child?"; "can transmission be prevented by condoms?",
"by selecting uninfected partners?") and participation in
prevention programs (needle exchange, methadone
replacement, partner education, condom distribution,
HIV counseling and testing, and receipt of AIDS/STI bro-
chures) were assessed. Both sets of variables were dichot-
omized: all answers correct versus other and receipt of any
intervention versus no intervention. We collected infor-
mation about injecting drug use and needle sharing using
different recall time intervals. For the analysis reported
here we used only the information about ever injecting
drugs and ever sharing needles.
Statistical analysis
During data cleaning 649 records were removed. In 621
cases no blood test was performed (blood samples were
either insufficient for conducting the HIV test, blood tak-
ing was not successful or the participants did not comply
with taking a blood sample). Respondents reporting first
drug use at age below 14 years (27 cases) were excluded.
When the fraction of missing responses for a specific vari-
able was larger than 5% missing responses were coded as
a separate category. The final sample size after data clean-
ing and exclusion of participants with missing responses
(for missing values < 5%) was 5128. We assessed the
effects of missing values on the results by repeating the
analysis with separate categories for missing values (N =
5593).
A Chi-square test with significance level p ≤ 0.05 was used
for evaluation of bivariate associations between socio-
demographic and behavioural risk factors and HIV status.
A joint analysis of all considered risk factors was carried
out using random effects multiple logistic regression [22].
First, an analysis including all variables was performed
with site as a grouping factor but without any covariates at
the site level. Second, we investigated whether thePage 3 of 11
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differences in the prevalence of HIV between regions. We
generated a variable containing the information about
prevalence in each region and included this as a site level
covariate in the model. Finally, differences between differ-
ent study sites were presented as frequencies of the
respondents with different characteristics using the sam-
ple of 5890 participants with available information. The
distribution of duration of drug use was analysed to assess
the composition of the regional samples and the epidemi-
ological situation of drug use in the regions.
Results
Characteristics of the total sample
In total, 6539 interviews were conducted in 21 surveil-
lance sites and 5918 blood specimens were tested. About
half of the respondents originated from detoxification
centres, one third from the community, and the remain-
der from other recruitment settings (Table 1). The sample
was predominantly male with 5.6:1 male-to-female ratio.
Age range was between 14 and 78 years, with a median of
30 years. Eighty percent of the participants initiated drug
use before age of 30 years; about half of the sample had
never injected drugs. Among the 2717 IDU 44.6% had
ever shared needles. Eighty seven percent of the respond-
ents had no commercial sex partners in last 12 months
before the interview, 2% had at least one sex partner with
a large variation in numbers, and for 11% the information
was missing. Among 85 respondents who had commer-
cial sex, 36.8% had used a condom during the last com-
mercial sex (not shown). In the 12 months before the
interview 14% of participants had experienced symptoms
that could be caused by STI.
Factors associated with HIV in the total sample
The overall HIV-1 antibody prevalence was 5.0%; 6.6%
among IDU and 3.5% among non-injecting drug users.
Bivariate analysis showed several associations between
Table 1: General characteristics of the study population (N = 5128), their bivariate association with HIV-1 antibody status, and results 
from random effects multiple regression model.
Variables Number % HIV+ p* OR (95% CI) p
Sample source Detoxification center 2871 56.0 5.8 0.002 1
Community 1621 31.6 4.0 0.77 (0.55–1.09) 0.143
Others1 636 12.4 7.6 0.66 (0.46–0.93) 0.019
Gender Male 4348 84.8 5.5 0.940 1
Female 780 15.2 5.4 0.73 (0.50–1.07) 0.111
Age <= 30 2676 52.2 6.2 0.012 1.04 (0.80–1.36) 0.750
> 30 2452 47.8 4.6 1
Marital status live without partner 2821 55.0 5.1 0.195 1
live with partner 2307 45.0 5.9 1.00 (0.79–1.27) 0.991
Place of residence Local 4393 85.7 5.9 < 0.001 1
Transient 735 14.3 2.5 1.27 (0.64–2.51) 0.490
Nation Han 3794 74.0 2.9 < 0.001 1
Minority 1334 26.0 12.7 1.38 (0.93–2.04) 0.107
Education <= 9 years 1710 33.4 9.0 < 0.001 1
> 9 years 3418 66.6 3.7 1.17 (0.89–1.53) 0.250
Profession white collar 1744 34.0 8.6 < 0.001 1.18 (0.85–1.64) 0.313
blue collar 3384 66.0 3.8 1
Monthly income <= 600 2147 41.9 6.9 < 0.001 1
601–2000 1127 22.0 4.5 1.56 (1.13–2.15) 0.007
> 2000 313 6.1 1.9 0.51 (0.24–1.08) 0.080
Missing 1541 30.1 4.7 1.05 (0.79–1.39) 0.751
Age at first drug use <= 30 4189 81.7 5.5 0.05 1
> 30 707 13.8 4.1 0.71 (0.48–1.05) 0.088
Missing 232 4.5 1.6 0.79 (0.38–1.65) 0.532
IDU and sharing needles (ever) no IDU 2411 47.0 3.7 < 0.001 1
IDU, no sharing of needles 1506 29.4 4.9 1.89 (1.37–2.61) < 0.001
IDU, sharing needles 1211 23.6 9.5 3.15 (2.29–4.33) < 0.001
Having commercial sex in last 12 months No 4455 86.9 5.5 0.148 1
Yes 85 1.7 9.4 1.33 (0.66–2.70) 0.4265
Missing information 588 11.5 4.4 0.73 (0.50–1.06) 0.102
STD symptoms in last 12 months No 4418 86.2 5.3 0.338 1
Yes 710 13.9 6.2 0.76 (0.55–1.05) 0.100
1Outreach programs, contacts of known IDU, unknown.
p* Chi-SquarePage 4 of 11
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prevalence was higher in participants who: were recruited
in detoxifications centres; were younger (≤ 30 years), were
resident versus transient; were from minority ethnic
groups versus Han-Chinese; had higher versus lower edu-
cation; had 'blue collar' versus 'white collar' jobs, had
higher incomes; were younger at first drug use; had ever
injected drugs; and had ever shared needles (Table 1, col-
umns 3 and 4).
Random effects multiple logistic regression analysis
showed fewer significant associations: income categories,
ever injecting drugs, ever sharing needles and recruitment
setting were associated with HIV status (Table 1, columns
5 and 6). Most prominent were the effects of ever injecting
drug use (OR = 1.9) without sharing needles or with shar-
ing needles (OR = 3.2) as compared to non-injecting drug
use. Participants in the middle income category had high-
est risk for being HIV positive. The analysis with all miss-
ing values recoded into separate categories yielded very
similar results (data not shown).
Overall, the impact of regional differences (as random
effects) was large, explaining 87% of the variation in the
sample. However, the heterogeneity across sites was sub-
stantially reduced after adjusting for regional differences
in HIV prevalence (explaining 62% of the total variation).
At the same time, the model prediction (and the strength
of the association between risk factors and HIV status)
considerably improved (area under the receiving operator
curve increased from 0.78 to 0.89). Since injecting drugs
(with and without needle sharing) was the most promi-
nent risk factor, only the interaction between this variable
and regional prevalence was investigated and there was no
statistical evidence of interaction (p > 0.05).
Regional diversity in the prevalence of HIV and in risk 
behaviours
There was a substantial heterogeneity among the surveil-
lance sites (Table 2). The HIV prevalence was higher in
three regions (21% in Guangxi Nanning, 29% in Sichuan
Liangshan and 10.8% in Xinjinag Kashi), up to 8% in 10
regions and no HIV cases were found in samples from 8
sites (Figure 1). The fraction of participants recruited in
detoxifications centres varied between 0% and 100%, the
proportion of participants who had never injected drugs
varied between 2% and 98%. On the other hand, between
0.3% and 71% were drug users who had injected drugs
and shared needles. Information regarding the number of
commercial sex partners in the last 12 months was miss-
ing for a substantial fraction of respondents making the
assessment of exposure difficult. There were also large dif-
ferences in the proportions of participants tested in the
past for HIV (7%–57%) and who participated in any drug
use and HIV related interventions (0%–75%). There was
also a substantial difference in the fraction of participants
who knew all the correct answers to questions related to
HIV ranging from 30% to 80%. Also, in terms of demo-
graphic aspects the samples strongly differed with the pro-
portion of female participants ranging from 0% to 49%
and the proportion of people from minority ethnic groups
from 0% to 98%. There was no clear pattern of differences
using cluster analysis; the only correlation between the
variables was found for the fraction of respondents tested
in the past for HIV and the fraction who participated in
any intervention in the past, which is not surprising.
Distribution of the duration of drug use as an indicator of 
epidemiologic stage
There were substantial differences with respect to the
duration of either any drug use or injecting drug use across
the sites (Figures 2 and 3). In several sites the median
duration was short (below 5 years) but in a few sites it was
substantially longer (approaching 10 years). The distribu-
tion of the duration of injecting drug use in most sites fol-
lowed the duration of any use, but the medians were
usually lower.
Discussion
The prevalence of HIV differed markedly between differ-
ent second generation surveillance sites, ranging from 0%
in eight sites to above 20% in two sites (21% in Guangxi
Nanning and 29.4% in Sichuan Liangshan). Both of the
high prevalence sites lie in provinces bordering Yunnan
province – the area where the HIV epidemic among IDU
in China first started – or Myanmar. The site in Kunming,
Yunnan, which was excluded from the analysis, had a
prevalence of 54.0%. Another site with relatively high
prevalence was Xinjiang Kashi with 10.8%, which is in the
northwest near the border with Afghanistan. In previous
years the prevalence in this site was found to be as high as
60% but in 2005 only some of the respondents were actu-
ally tested for HIV, so the estimate of 10.8% is probably
an underestimate of the true prevalence. These results are
similar to the regional distribution of HIV prevalence in
China found in earlier surveillance data [3].
Whereas known risk factors like injecting drugs or sharing
needles were associated with HIV infection at the individ-
ual level in logistic regression, they were not associated
with HIV prevalence at the population level. On the con-
trary, the uncertainty in relating risk behaviour to being
infected was greatly reduced when local HIV prevalence
was taken into account in the model. This can be seen as
an indication of the different phases of the HIV epidemic
in different geographical regions, with some regions
already heavily affected and others still at the beginning of
a large outbreak. Risk behaviours like needle sharing were
highly prevalent in many regions, including those with
low HIV prevalence, indicating the potential for HIVPage 5 of 11
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Table 2: Prevalence and risk factors for HIV infection among drug users in all surveillance sites.
Sites Total HIV prevalence % 
(95% CI)
From 
detoxification 
center %
IDU and needle-sharing – ever (%) Number of commercial sex partners in last 
12 months (%)
Tested for HIV 
in the past %
Participated in any 
intervention %
Knows all 
answers %
Female % Ethnic 
minority %
IDU without 
needle-sharing
IDU with 
needle-sharing
None Any Missing
1 Hebei 
Shijiazhuang
361 0.0 
(0.0–1.1)
13.0 47.1 19.8 95.0 0.3 4.7 24.1 17.7 65.1 18.8 3.5
2 Liaoning 
Fushun
28 0.0 
(0.0–12.1)
26.7 25.0 71.4 92.9 0.0 7.1 39.3 35.7 50.0 0 0
3 Anhui 
Huainan
113 0.0 
(0.0–3.2)
0 33.6 19.5 89.4 0.9 9.7 51.3 0 65.5 28.3 2.7
4 Anhui 
Maanshan
141 0.7 
(0.1–3.9)
0 65.0 19.3 92.9 0.7 6.4 36.2 9.9 80.1 33.3 3.6
5 Zhejiang 
Hangzhou
267 0.0 
(0.0–1.4)
99.3 32.8 20.1 91.8 0.4 7.9 22.5 39.0 68.9 29.6 4.5
6 Hubei 
Jingzhou
409 0.5 
(0.1–1.8)
98.1 41.9 28.6 89.2 2.9 7.8 21.3 26.2 79.5 14.4 0.2
7 Hubei 
Xiaogan
352 0.9 
(0.3–2.5)
72.1 37.7 19.1 77.0 0.3 22.7 7.4 66.2 74.7 27.3 2.9
8 Guangdong 
Dongguan
407 5.9 
(4.0–8.6)
39.2 44.8 21.9 76.9 4.4 18.7 57.0 11.1 37.3 9.8 11.8
9 Guangxi 
Nanning
291 21.0 
(16.7–26.0)
53.2 44.0 53.6 90.0 2.1 7.9 12.4 75.3 74.2 49.1 17.3
10 Chongqing 368 7.3 
(5.1–10.5)
63.7 38.8 52.2 77.4 1.1 21.5 37.2 28.5 62.5 0 .3
11 Guizhou 
Qianxinan
363 0.3 
(0.1–1.6)
99.8 32.6 22.1 74.7 2.5 22.9 27.5 3.6 60.1 18.7 19.8
12 Guizhou 
Tongren
376 4.5 
(2.8–7.1)
49.9 30.6 26.9 72.3 1.3 26.3 19.7 37.2 30.3 27.1 53.3
13 Sichuan 
Dazhou
223 0.4 
(0.1–2.5)
50.0 58.7 33.0 73.1 4.9 22.0 28.3 7.6 57.4 20.6 .5
14 Sichuan 
Leshan
189 2.6 
(1.1–6.1)
56.5 14.9 61.2 98.4 0.5 1.1 41.3 69.3 51.3 15.9 2.8
15 Sichuan 
Liangshan
415 29.4 
(25.2–34.0)
76.7 15.4 20.8 90.1 1.9 8.0 26.7 12.0 49.6 6.7 94.9
16 Gansu Dingxi 193 0.0 
(0.0–2.0)
64.5 1.0 1.0 100.0 0.0 0.0 38.9 6.2 42.5 3.6 3.2
17 Gansu 
Wuwei
357 0.0 
(0.0–1.1)
44.6 1.4 0.3 98.3 0.3 1.4 34.2 1.7 56.3 3.6 12.0
18 Qinghai 
Haidong
163 0.6 
(0.1–3.4)
0 8.1 21.2 96.9 0.0 3.1 10.4 62.0 40.5 7.4 49.1
19 Qinghai Haixi 478 0.0 
(0.0–0.8)
62.6 3.6 2.1 95.6 0.4 4.0 50.6 11.3 60.3 3.8 35.4
20 Xinjiang 
Kashi
297 10.8 
(7.7–14.8)
17.2 12.5 5.1 94.9 3.4 1.7 23.9 14.8 38.0 3.4 98.3
21 Xinjiang Yili 99 0.0 
(0.0–3.7)
56.9 46.9 34.7 92.9 0.0 7.1 22.2 41.4 72.7 0 98.0
BMC Infectious Diseases 2008, 8:108 http://www.biomedcentral.com/1471-2334/8/108spread in as yet unaffected regions. Interestingly, the tim-
ing of drug use and HIV epidemics differ between sites
with some having a well established (injecting) drug use
epidemic with low or high HIV prevalence and others
where (injecting) drug use and possibly HIV are newly
emerging (Figures 2 and 3). In view of the fact that drug
users at the beginning of their injecting career are at
increased risk of contracting blood borne infections [23-
25] the distribution of exposure times can provide impor-
tant information about the potential for future expansion
of the HIV epidemic and for targeting interventions. Inter-
ventions were not associated with risk reduction or with a
higher knowledge regarding HIV at the regional level.
Judging from the distributions of drug use duration in dif-
ferent sites we conclude that sites with mature drug use
epidemics lie in the south of the country around Yunnan
province, then there is a band with sites where both long
Sentinel sites for second generation surveillance among drug users in 2005, in brackets the HIV-1 prevalenceFigur  1
Sentinel sites for second generation surveillance among drug users in 2005, in brackets the HIV-1 prevalence. 
Green dots mark sites with HIV prevalence < 1%, yellow dots sites with HIV prevalence between 1% and 10%, and red dots 
sites with HIV prevalence > 10%. 1 Hebei Shijiazhuang (0%). 2 Liaoning Fushun (0%). 3 Anhui Huainan (0%). 4 Anhui Maanshan 
(0.7%). 5 Zhejiang Hangzhou (0%). 6 Hubei Jingzhou (0.5%). 7 Hubei Xiaogan (0.9%). 8 Guangdong Dongguan (5.9%). 9 Guangxi 
Nanning (21.0%). 10 Chongqing (7.3%). 11 Guizhou Qianxinan (0.4%). 12 Guizhou Tongren (4.5%). 13 Sichuan Dazhou (0.4%). 
14 Sichuan Leshan (2.6%). 15 Sichuan Liangshan (29.4%). 16 Gansu Dingxi (0%). 17 Gansu Wuwei (0%)). 18 Qinghai Haidong 
(0.6%. 19 Qinghai Haixi (0%). 20 Xinjiang Kashi (10.8%). 21 Xinjiang Yili (0%).Page 7 of 11
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BMC Infectious Diseases 2008, 8:108 http://www.biomedcentral.com/1471-2334/8/108term and new drug users are found in the samples, and
finally there are some sites with mainly new drug users.
Participants were asked whether they were tested in the
past for HIV, but not what their results were. Since a pos-
itive test result could have been associated with behav-
ioural changes, we did not include current risk behaviour
in the risk analysis model. For the same reason the assess-
ment of current risk behaviour in a regional sample with
high HIV prevalence could be biased. Therefore, in the
analysis of risk factors for HIV we only used the informa-
tion on ever injecting drugs and ever sharing needles. On
the other hand, since there was no assessment of sexual
risk behaviour in terms of ever/never, we used the infor-
mation about the last 12 months. Clearly, this informa-
tion could be misleading if behavioural changes followed
a positive HIV test. The difficulty could be remedied if the
questions about having been previously tested for HIV
were complemented by asking about time and result of
the test. Also having symptoms of sexually transmitted
infections in the last 12 months cannot be simply inter-
preted as a proxy for a behavioural risk factor because
these might facilitate the transmission of HIV infection.
A major limitation of the data set is the lack of a system-
atic sampling frame across the different sites. The marked
heterogeneity in recruitment settings, with some samples
coming mainly from detoxification centres and others
from the drug user community makes any comparison
between sites questionable. In particular, if detoxification
is enforced by law as reported in [14] the selection of sur-
vey participants would be strongly biased. The represent-
ativeness of community-based samples is also unknown,
although in some settings results obtained from conven-
ience sampling or even snowball sampling can be unbi-
ased [26,27].
Sampling from different subgroups of the drug user pop-
ulation might influence the distribution of duration of
drug use. This might explain the striking difference in HIV
prevalence between the two sites located in Xinjiang prov-
ince. Also, the high HIV prevalence in Xinjiang Kashi
among drug users who had just started their drug using
career could have resulted from a sampling bias. Problems
with lack of systematic sampling frames for drug users
have been discussed extensively in the literature and the
inherent difficulties have to be acknowledged [27]. Drug
use is illegal in nearly all countries and stigmatised in
most societies [28] so drug users are likely to hide their
activities and avoid contacts associated with disclosure of
drug use. In order to reduce these kinds of behaviours and
increase participation in the study, our data collection
procedures ensured that there was no threat of prosecu-
tion. Difficulties with reporting of illegal behaviour might
also extend to other areas where some responses are
socially desirable, resulting in missing values and untruth-
ful responses. This might have occurred in this survey with
the reporting of sexual behaviour. Several methods have
been proposed for controlling social desirability bias and
should be included in further studies of drug users [29].
The distribution of the duration of drug use (age of respondent minus age at first drug use) in sites with low HIV prevalence (< 1%) (Blue boxplots – any drug use, green – injecting drug us  a o g IDU)Figure 2
The distribution of the duration of drug use (age of respondent minus age at first drug use) in sites with low 
HIV prevalence (< 1%) (Blue boxplots – any drug use, green – injecting drug use among IDU).
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BMC Infectious Diseases 2008, 8:108 http://www.biomedcentral.com/1471-2334/8/108Recently, the so-called 'respondent driven sampling'
method has been developed to ensure access to drug users
who cannot be reached by prevention or health care work-
ers [30,31]. Respondent driven sampling offers the oppor-
tunity to develop quantitative estimates of HIV prevalence
based on the sample obtained with a sampling frame fol-
lowing strict rules in participant recruitment. However,
the method is still being developed and its reliability has
to be further investigated [32].
Second generation surveillance for injecting drug users
should be further enhanced by surveys assessing knowl-
edge and attitudes about risk behaviour, population size
estimates for hidden populations, and hepatitis C surveil-
lance [33]. While questions about knowledge of risk
behaviours are already part of second generation surveil-
lance in China, monitoring of hepatitis C could be a valu-
able addition. As the prevalence of hepatitis C in
beginning injectors is seen as a proxy for incidence of new
infections, changes in young injectors' hepatitis C preva-
lence can indicate changes in injecting risk behaviour.
The distribution of the duration of drug use (age of respondent minus age at first drug use) in sites with medium and high HIV prevalence (≥ 1%) (Blue boxplots – any drug us , gre n – inj c ing drug use among IDU)Figur  3
The distribution of the duration of drug use (age of respondent minus age at first drug use) in sites with 
medium and high HIV prevalence (≥ 1%) (Blue boxplots – any drug use, green – injecting drug use among IDU).
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BMC Infectious Diseases 2008, 8:108 http://www.biomedcentral.com/1471-2334/8/108Conclusion
In conclusion, there are two main findings of this study.
First, risk behaviours are prevalent among drug users in
China and provide substantial potential for HIV spread in
not yet affected regions. Second, methodological limita-
tions of surveillance embedded into routine systems limit
the usability of existing data. One of the goals of second
generation surveillance according to WHO guidelines is
the "better use of surveillance data to increase understand-
ing and to plan prevention and care" [21]. Only when sur-
veillance data lead to an understanding of the epidemic
process can effective interventions be implemented. To
reach that goal it is advisable that more care be taken to
ensure standardized data collection. More capacity and
support should be given to surveillance sites to make the
investment into second generation surveillance worth the
effort.
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